Garcia
Principal executive officer pay for Garcia, by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
Dianthus Therapeutics, Inc. /DE/ (DNTH) FY2023–FY2025
Aligned: paid up as stock roseCAP $343,583→$16,739,215 while $100 invested went $14.67→$652.06
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2023 | $496,022 | $343,583 |
| FY2024 | $8.8M | $12.0M |
| FY2025 | $10.6M | $16.7M |
The company's "$100 invested" index ran $14.67 at FY2023 → $652.06 by FY2025 — an annualized return of 566.7%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 566.7%/yr at DNTH ( FY2023–FY2025). See the CEO track-record ranking for context.